SPPORT intensification did not worsen long-term quality of life
Short-term androgen deprivation impaired early sexual and hormonal quality of life, but treatment-arm differences were not clinically significant at five years.
Short-term androgen deprivation impaired early sexual and hormonal quality of life, but treatment-arm differences were not clinically significant at five years.
Escalating metabolically active disease to 73.5 Gy did not improve locoregional control, disease-free survival, or overall survival versus 66 Gy.
Once-weekly prostate-and-pelvis SBRT reduced acute gastrointestinal toxicity versus conventional IMRT without significantly increasing genitourinary toxicity.
Concurrent neoadjuvant radiotherapy shortened treatment duration but did not improve pathological complete response or survival.
Single-fraction GammaPod partial breast irradiation produced 12.1% fat necrosis and 4.1% symptomatic fat necrosis in a phase 2 trial.
TREASURE found no survival benefit and higher serious toxicity with thoracic radiotherapy added to atezolizumab maintenance.
Single-fraction proton treatment produced pain responses without grade 2 or higher related toxicity in 10 patients with thoracic bone metastases.